Advertisement

U.S. markets closed

S&P Futures
4,280.00
-6.50(-0.15%)
Dow Futures
33,948.00
-33.00(-0.10%)
Nasdaq Futures
13,500.25
-23.00(-0.17%)
Russell 2000 Futures
1,996.30
-5.40(-0.27%)
Crude Oil
90.64
+0.14(+0.15%)
Gold
1,768.90
-2.30(-0.13%)

Advertisement

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

209.06

-3.96

(-1.86%)

At close: 04:00PM EDT

209.00

-0.06

(-0.03%)

After hours:

07:59PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	213.02
Open	213.00
Bid	208.11 x 800
Ask	212.88 x 1000
Day's Range	207.10 - 213.49
52 Week Range	173.45 - 492.29
Volume	1,022,597
Avg. Volume	1,511,750

Market Cap	32.885B
Beta (5Y Monthly)	1.14
PE Ratio (TTM)	47.09
EPS (TTM)	4.44
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	241.41

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ILMN

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Illumina, Inc.
Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Rating
Fair Value
Economic Moat
7 days agoMorningstar

All

Motley Fool
2 Red Flags and 1 Green Flag For Illumina Stock
Its sequencing devices are among the most widely distributed in global hospitals and laboratories of all stripes, and its ongoing years-long efforts to develop new technologies place it at the cutting edge of the field, with few notable competitors anywhere in sight. Illumina is currently facing some serious legal trouble in the E.U. to the point where it constitutes a red flag for its near-term performance. To prepare for the possible fine, Illumina is setting aside $453 million.
Zacks
Is Trending Stock Illumina, Inc. (ILMN) a Buy Now?
Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Should Value Investors Buy Bassett Furniture Industries (BSET) Stock?
  Zacks
- Is HarleyDavidson (HOG) a Great Value Stock Right Now?
  Zacks
Insider Monkey
Baron Funds: “We Expect Illumina(ILMN) to Continue to Innovate & Introduce New Products”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […]